Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

5 Dividend Stocks to Buy and Hold Forever

The article highlights five blue-chip dividend stocks suitable for long-term buy-and-hold investing: AbbVie, McDonald's, Johnson & Johnson, Walmart, and Becton Dickinson. These companies have demonstrated decades of consecutive dividend increases and strong financial fundamentals, with dividends well-covered by earnings and solid growth prospects ahead.

06/22/2026, 6:15 AM • The Motley Fool

Global Hyperpigmentation Treatment Market Size to Surpass USD 2.85 Billion by 2035, Growing at a 6.5% CAGR – SNS Insider

The global hyperpigmentation treatment market is projected to grow from USD 1.52 billion in 2025 to USD 2.85 billion by 2035, expanding at a 6.5% CAGR. Growth is driven by increased consumer awareness of skin aesthetics, rising prevalence of pigmentation conditions like melasma, and adoption of advanced treatments including laser therapy and microneedling. The U.S. market is expected to reach USD 0.93 billion while Europe approaches USD 0.81 billion by 2035.

06/21/2026, 10:25 PM • GlobeNewswire

Smart Money Is Fleeing Tech for Johnson & Johnson Ahead of the Next Market Storm

With technology stocks comprising nearly 40% of the S&P 500's value, investors are advised to diversify into more resilient sectors like healthcare. Johnson & Johnson is highlighted as an attractive alternative due to its Dividend King status (50+ consecutive years of dividend increases), strong innovation through R&D, and the defensive nature of healthcare, which tends to be more stable during market downturns compared to volatile tech stocks.

06/19/2026, 1:15 PM • The Motley Fool

Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider

The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.

06/19/2026, 5:39 AM • GlobeNewswire

Legend Biotech Corporation Announces Pricing of Public Offering

Legend Biotech Corporation announced the pricing of an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million in gross proceeds. The offering is expected to close on June 23, 2026, with Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities serving as joint book-running managers.

06/17/2026, 9:21 PM • GlobeNewswire

Billionaire Ken Griffin Sold Amazon and Nvidia but Quietly Loaded Up on This Healthcare Giant

Ken Griffin's Citadel Advisors reduced positions in Nvidia and Amazon during Q1 while increasing its stake in Intuitive Surgical by 30.3%. Despite the medical device company facing headwinds from competition, lower margins on new products, and tariffs, analysts believe its strong competitive moat, large addressable market, and AI integration potential make it an attractive long-term investment at current valuations.

06/16/2026, 4:30 PM • The Motley Fool

Over 100 Organizations Thank America’s Blood Donors on World Blood Donor Day

More than 100 prominent organizations have united to promote World Blood Donor Day on June 14, 2026, and Blood Advocacy Week (June 8-12). The initiative highlights that while blood transfusions are needed every 2 seconds in America, less than 3% of eligible Americans donate blood. The campaign theme is 'One Drop of Humanity. Give Blood. Save Lives.' emphasizing the critical need for volunteer blood donors.

06/14/2026, 8:54 AM • GlobeNewswire

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Legend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable safety profile showing no dose-limiting toxicities, serious adverse events, or ICANS.

06/14/2026, 3:15 AM • GlobeNewswire

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson announced Phase 3 MonumenTAL-3 study results showing TALVEY® (talquetamab), a GPRC5D bispecific antibody, combined with daratumumab with or without pomalidomide achieved 81.3% progression-free survival and 89.2% overall survival at 24 months in relapsed or refractory multiple myeloma patients, significantly outperforming standard care. The company has submitted a regulatory variation to the EMA for approval of this combination therapy.

06/13/2026, 6:41 AM • GlobeNewswire

Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most "Undruggable" Targets. Why That's Very Good News for Investors.

Johnson & Johnson acquired Firefly Bio for $1 billion to gain access to its Firelink degrader antibody conjugate (DAC) platform, which targets KRAS-driven tumors previously considered 'undruggable.' This acquisition supports J&J's goal of generating $50 billion in annual oncology revenue by 2030, as the antibody drug conjugate market is projected to reach $21-35 billion by 2030-2035.

06/12/2026, 2:05 PM • The Motley Fool

AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

AbbVie presented 21 clinical presentations on blood cancer therapies at the European Hematology Association Congress, showcasing progress in its oncology portfolio which generated $6.7 billion in 2025 revenue. The company's diversified pipeline across immunology, oncology, and neuroscience is helping offset Humira's patent-driven decline and could support future dividend growth through expanded cash flow.

06/12/2026, 6:15 AM • The Motley Fool

Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?

Parabilis Medicines raised $670 million in the largest biotech IPO on record, soaring 58% on its first trading day. The company's innovative Helicon platform targets previously 'undruggable' proteins for cancer treatment. While the technology shows promise with lead candidate zolucatetide entering phase 3 trials, the company faces significant losses ($145 million last year) and remains years away from generating revenue, making it suitable only for aggressive investors willing to wait several years.

06/12/2026, 2:30 AM • The Motley Fool

Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder

Johnson & Johnson announced that IMAAVY (nipocalimab-aahu) achieved its primary endpoint in the Phase 2/3 ENERGY study for warm autoimmune hemolytic anemia (wAIHA). Patients receiving the 30 mg/kg dose were three times more likely to achieve durable hemoglobin improvements compared to placebo over 24 weeks. The drug demonstrated rapid onset of effect, early improvements in fatigue, and reduced steroid use, with a safety profile consistent with its approved indication in myasthenia gravis. The supplemental Biologics License Application has been granted FDA Priority Review.

06/11/2026, 12:40 PM • Benzinga

ThruFlo Endovascular Secures Seed Funding to Advance First Purpose-Built Flow Diverter for Bifurcation Aneurysms

ThruFlo Endovascular announced completion of seed funding led by Atlas MedInnovation to develop a novel bifurcated flow diverter for treating cerebral aneurysms at vessel branch points. The device addresses a significant gap in the market where approximately 60% of intracranial aneurysms occur. Proceeds will fund R&D operations, device design completion, pre-clinical studies, and FDA IDE application submission.

06/10/2026, 3:40 PM • GlobeNewswire